Caribou Biosciences, Inc. Operating Cash Flow
Caribou Biosciences, Inc. (CRBU) reported Operating Cash Flow of -$49.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.79M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$26.98M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$20.82M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$25.18M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$110.99M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$138.20M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$93.29M.
- Caribou Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$90.97M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$49.77M 10-Q · filed 2026-08-13 | -$70.59M derived: sum of 3 quarters · filed 2026-08-13 | -$95.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$26.98M 10-Q · filed 2026-05-07 | -$47.81M derived: sum of 2 quarters · filed 2026-05-07 | -$72.99M derived: sum of 3 quarters · filed 2026-05-07 | -$101.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$20.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$46.01M derived: sum of 2 quarters · filed 2026-03-05 | -$74.27M derived: sum of 3 quarters · filed 2026-08-13 | -$110.99M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$25.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$53.44M derived: sum of 2 quarters · filed 2026-08-13 | -$90.17M 10-Q · filed 2025-11-12 | -$125.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$28.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$64.98M 10-Q · filed 2026-08-13 | -$100.45M derived: sum of 3 quarters · filed 2026-08-13 | -$133.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$36.73M 10-Q · filed 2026-05-07 | -$72.19M derived: sum of 2 quarters · filed 2026-05-07 | -$104.86M derived: sum of 3 quarters · filed 2026-05-07 | -$137.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$35.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$68.13M derived: sum of 2 quarters · filed 2026-03-05 | -$101.00M derived: sum of 3 quarters · filed 2026-03-05 | -$138.20M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$32.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$65.53M derived: sum of 2 quarters · filed 2025-11-12 | -$102.73M 10-Q · filed 2025-11-12 | -$124.11M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$32.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$70.07M 10-Q · filed 2025-08-12 | -$91.45M derived: sum of 3 quarters · filed 2025-08-12 | -$120.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$37.20M 10-Q · filed 2025-05-08 | -$58.58M derived: sum of 2 quarters · filed 2025-05-08 | -$87.37M derived: sum of 3 quarters · filed 2025-05-08 | -$102.56M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$21.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$50.17M derived: sum of 2 quarters · filed 2025-03-10 | -$65.35M derived: sum of 3 quarters · filed 2025-03-10 | -$93.29M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$28.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$43.97M derived: sum of 2 quarters · filed 2024-11-06 | -$71.91M 10-Q · filed 2024-11-06 | -$96.96M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$15.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$43.12M 10-Q · filed 2024-08-06 | -$68.17M derived: sum of 3 quarters · filed 2024-08-06 | -$90.54M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$27.94M 10-Q · filed 2024-05-07 | -$52.98M derived: sum of 2 quarters · filed 2024-05-07 | -$75.36M derived: sum of 3 quarters · filed 2024-05-07 | -$97.23M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$25.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$47.42M derived: sum of 2 quarters · filed 2024-03-11 | -$69.29M derived: sum of 3 quarters · filed 2024-03-11 | -$90.97M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$22.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$44.25M derived: sum of 2 quarters · filed 2023-11-07 | -$65.92M 10-Q · filed 2023-11-07 | -$87.31M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$21.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$43.55M 10-Q · filed 2023-08-08 | -$64.94M derived: sum of 3 quarters · filed 2023-08-08 | -$79.90M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$21.67M 10-Q · filed 2023-05-09 | -$43.06M derived: sum of 2 quarters · filed 2023-05-09 | -$58.03M derived: sum of 3 quarters · filed 2023-05-09 | -$74.50M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$21.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$36.36M derived: sum of 2 quarters · filed 2023-03-09 | -$52.83M derived: sum of 3 quarters · filed 2023-03-09 | -$32.52M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$14.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$31.44M derived: sum of 2 quarters · filed 2022-11-08 | -$11.13M 10-Q · filed 2022-11-08 | -$19.21M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$16.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.84M 10-Q · filed 2022-08-09 | -$4.24M derived: sum of 3 quarters · filed 2022-08-09 | -$12.93M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $20.31M 10-Q · filed 2022-05-09 | $12.24M derived: sum of 2 quarters · filed 2022-05-09 | $3.55M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$16.77M derived: sum of 2 quarters · filed 2022-03-21 | -$33.22M 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$25.14M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$16.45M 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | -$32.01M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |